Comparative study on morning and evening regimens of fleroxacin for the treatment of complicated urinary tract infections

M. Takeda, K. Noguchi, M. Masuda, M. Yao, Y. Kinoshita, M. Hosaka, S. Fukushima, C. Kawasaki, T. Murai, Y. Satomi, M. Fukuda, T. Kodaira, K. Miyai, K. Sano, T. Ishido, K. Tanaka, K. Sato, H. Kanno, Y. Senga, H. KumagaiT. Takahashi, K. Saito, H. Fukuoka, K. Kitami, H. Shimura, H. Shiozaki, H. Miyamoto

Research output: Contribution to journalReview articlepeer-review

Abstract

We performed a prospective randomized study to evaluate the effectiveness and safety of once-daily administrations of fleroxacin (FLRX) for the treatment of complicated urinary tract infections. A comparative study was conducted with administration of 200mg FLRX once a day, after breakfast or after dinner, for 7 days. Of a total 167 cases, 62 cases in the morning-administration group and 61 cases in the evening-administration group were evaluated under the criteria proposed by the Japanese UTI committee. The overall clinical efficacy was 67.7% in the morning group and 55.7% in the evening group. No significant difference was revealed between these two groups. Clinical adverse reactions were recognized in 3 cases in the morning group (85 cases) and 1 case in the evening group (80 cases). Abnormal laboratory findings were found in one case in the morning group. As a result, there were no significant differences in the effectiveness and safety of FLRX, regardless of the timing of administration. It was suggested that the timing of the administration of FLRX can be arranged to fit in with the lifestyle of the patients and the drug shows good compliance.

Original languageEnglish (US)
Pages (from-to)733-744
Number of pages12
JournalNishinihon Journal of Urology
Volume60
Issue number10
StatePublished - 1998
Externally publishedYes

Keywords

  • Complicated urinary tract infection
  • FLRX
  • Fleroxacin

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Comparative study on morning and evening regimens of fleroxacin for the treatment of complicated urinary tract infections'. Together they form a unique fingerprint.

Cite this